Valuation: Kadimastem

Market Cap 48.72M 0 15.6M 13.99M 12.94M 11.72M 21.89M 1.49B 22.15M 155M 61.61M 777M 58.52M 57.29M 2.47B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 48.72M 0 15.6M 13.99M 12.94M 11.72M 21.89M 1.49B 22.15M 155M 61.61M 777M 58.52M 57.29M 2.47B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
34.42%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 15.6M
+0.34%-3.03%+37.45%+61.06% 64.14B
+1.05%+2.73%+12.31%+84.00% 55.53B
+1.33%+1.56%+12.80%+104.82% 53.03B
-0.52%-0.06%+27.69%+57.00% 45.99B
-0.37%-2.46%+18.42%+99.81% 42.45B
+0.74%+1.76%+229.20%+940.87% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.54%+103.50%+90.01% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.25%+3.82%+52.76%+164.12% 43.62B
Weighted average by Cap. -0.01%+3.13%+49.82%+161.71%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11